Back

Homologous and Heterologous Vaccine Boost Strategies for Humoral and Cellular Immunologic Coverage of the SARS-CoV-2 Omicron Variant

Tan, C. S.; Collier, A.-r.; Liu, J.; Yu, J.; Chandrashekar, A.; McMahan, K.; Wan, H.; He, X.; Jacob-Dolan, C.; Sellers, D.; Ventura, J.; Bartsch, Y.; Hauser, B.; Munt, J.; Mattocks, M.; Stephenson, K.; Vidal, S.; Jaegle, K.; Rowe, M.; Hemod, R.; Bermudez Rivera, L.; Anioke, T.; Barrett, J.; Chung, B.; Gardner, S.; Gebre, M.; Hachmann, N.; Lifton, M.; Miller, J.; Nampanya, F.; Powers, O.; Sciacca, M.; Siamatu, M.; Surve, N.; Tostanoski, L.; VanWyk, H.; Wu, C.; Baric, R. S.; Schmidt, A.; Alter, G.; Barouch, D.

2021-12-30 infectious diseases
10.1101/2021.12.02.21267198 medRxiv
Show abstract

The rapid spread of the highly mutated SARS-CoV-2 Omicron variant has raised substantial concerns about the protective efficacy of currently available vaccines. We assessed Omicron-specific humoral and cellular immune responses in 65 individuals who were vaccinated with two immunizations of BNT162b2 and were boosted after at least 6 months with either Ad26.COV2.S (Johnson & Johnson; N=41) or BNT162b2 (Pfizer; N=24) (Table S1). O_TBL View this table: org.highwire.dtl.DTLVardef@41c8baorg.highwire.dtl.DTLVardef@e14f5forg.highwire.dtl.DTLVardef@21ea87org.highwire.dtl.DTLVardef@ac4522org.highwire.dtl.DTLVardef@1eed52b_HPS_FORMAT_FIGEXP M_TBL O_FLOATNOTable S1.C_FLOATNO O_TABLECAPTIONCharacteristics of the study population C_TABLECAPTION C_TBL

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Nature Communications
○ 5641 papers in training set
Top 10%
18.2%
Similar papers in this journal
2
Science Translational Medicine
● 127 papers in training set
Top 0.1%
14.8%
Similar papers in this journal
3
Nature Medicine
○ 125 papers in training set
Top 0.2%
7.1%
Similar papers in this journal
4
New England Journal of Medicine
● 52 papers in training set
Top 0.1%
6.6%
Similar papers in this journal
5
Cell
○ 431 papers in training set
Top 1%
5.4%
Similar papers in this journal
50% of probability mass above
6
Nature
○ 645 papers in training set
Top 3%
4.3%
7
Immunity
○ 67 papers in training set
Top 0.4%
4.2%
8
Science
● 477 papers in training set
Top 2%
4.2%
9
Cell Reports Medicine
○ 153 papers in training set
Top 0.7%
4.0%
10
Cell Reports
○ 1498 papers in training set
Top 12%
3.2%
11
Med
○ 39 papers in training set
Top 0.1%
2.7%
12
Clinical Infectious Diseases
◐ 235 papers in training set
Top 1%
2.3%
13
Journal of Clinical Investigation
● 179 papers in training set
Top 3%
1.9%
14
The Lancet Infectious Diseases
○ 73 papers in training set
Top 0.6%
1.7%
15
Cell Host & Microbe
126 papers in training set
Top 1%
1.7%
16
mBio
● 833 papers in training set
Top 8%
1.5%
17
eBioMedicine
○ 183 papers in training set
Top 4%
1.3%
18
Science Immunology
● 88 papers in training set
Top 2%
1.3%
19
Proceedings of the National Academy of Sciences
● 2444 papers in training set
Top 35%
1.1%
20
Nature Immunology
○ 79 papers in training set
Top 2%
1.1%
21
npj Vaccines
○ 67 papers in training set
Top 0.7%
1.0%
22
Cell Discovery
○ 57 papers in training set
Top 1%
0.8%
23
The Journal of Infectious Diseases
◐ 202 papers in training set
Top 4%
0.6%
24
JCI Insight
● 277 papers in training set
Top 9%
0.6%

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.